Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 4/20 | 0.69 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25190504 | 0.86 | PTK2 (0.59) | NNMTPTK2EPHX2CYP1A2GAA | |
| SCHEMBL7093993 | 0.85 | PTK2 (0.62) | NNMTPTK2CYP1A2GAASMN1; SMN2 | |
| SCHEMBL82675 | 0.84 | HCAR3 (0.68) | PTK2CYP1A2GAAHCAR3 | |
| SCHEMBL2746891 | 0.83 | NNMT (0.61) | NNMTEPHX2SMN1; SMN2HCAR3 | |
| SCHEMBL28157252 | 0.83 | NNMT (0.70) | NNMTEPHX2SMN1; SMN2HCAR3 | |
| Acetone SCHEMBL17558521 | 0.82 | NNMT (0.69) | NNMTEPHX2SMN1; SMN2HCAR3 | |
| SCHEMBL4320704 | 0.81 | NNMT (1.00) | NNMTEPHX2SMN1; SMN2HCAR3 | |
| SCHEMBL5537643 | 0.81 | NNMT (0.63) | NNMTEPHX2SMN1; SMN2 | |
| SCHEMBL19151094 | 0.81 | NNMT (0.63) | NNMTEPHX2SMN1; SMN2HCAR3 | |
| SCHEMBL3466195 | 0.81 | NNMT (0.63) | NNMTEPHX2SMN1; SMN2HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10568913-B2 | Method for generating mature β-like cells | HEALTHREGEN PTY LTD (AU) | 2020-02-25 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20160045554-A1 | METHOD FOR GENERATING MATURE BETA-LIKE CELLS | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2016-02-18 | — | — | US | disclosed |
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| EP-2429993-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2015-01-21 | — | — | EP | disclosed |
| WO-2014153620-A1 | METHOD FOR GENERATING MATURE β-LIKE CELLS | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2014-10-02 | — | — | WO | disclosed |
| US-8841331-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2285783-B1 | INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-05-21 | — | — | EP | disclosed |
| US-8338441-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-8338441-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8263597-B2 | Indazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20110294808-A1 | Indazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| WO-2010130034-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2009134666-A1 | INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-05 | — | — | WO | disclosed |
| US-4258052-A | APPLYING TOPICALLY | YU RUEY J | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | NNMT 1562/4885PTK2 3126/4885EPHX2 2057/4885 |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, RTF1 | NNMT 790/4885PTK2 4152/4885EPHX2 4374/4885 |
| US-20110294808-A1 | Indazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCRL2 | NNMT 2331/4885PTK2 1504/4885EPHX2 1772/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | NNMT 957/4885PTK2 2595/4885EPHX2 808/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | NNMT 100/4885PTK2 4052/4885EPHX2 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.